Form 8-K for BLUEBIRD BIO, INC.
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
On June 15, 2015, bluebird conducted an investor webcast summarizing clinical data from its HGB-205 clinical trial that was presented at an oral presentation at the 20th European Hematology Association Congress in Vienna, Austria on June 13, 2015. A copy of the presentation is being furnished as Exhibit 99.3 to this Report on Form 8-K.
The information in Item 7.01 of this Report on Form 8-K and Exhibits 99.2 and 99.3 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing
Exhibit No. Description 99.1 Press release issued by bluebird bio, Inc. on June 13, 2015. 99.2 Press release issued by bluebird bio, Inc. on June 15, 2015. 99.3 Investor presentation provided by bluebird bio, Inc. on June 15, 2015.